SciFi Advisor
Event-driven, biotech, healthcare, small-cap

Ohr Pharmaceutical: Eye Drop Treatment For Wet AMD Could Sideline Eylea Momentum

Patients with neovascular age-related macular degeneration (wet-AMD) have some solid treatment options that can decrease the amount of visual acuity loss due to the disease. Roche's (OTCQX:RHHBY) Lucentis is the most commonly recognized of the treatments and was approved in 2006, bringing in $1.5 billion in sales for 2012. A newer therapeutic, Regeneron's (NASDAQ:REGN) Eylea, has gone on an explosive run, increasing sales in 1Q 2013 nearly 90% from 1Q2012, with sales of $837.9 million for 2012, the first year of FDA approval. However, both of these treatments, and others not mentioned, require patients to undergo an intravitreal injection. An intravitreal injection is literally an injection directly into the eye, targeting the vitreous humor,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details